Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18396739 | 0.97 | ALDH1A1 (0.44) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL3043208 | 0.94 | ALDH1A1 (0.54) | MAPTALDH1A1KMT2ATHRBKDM4E | |
| SCHEMBL28196822 | 0.86 | ALDH1A1 (0.46) | MAPTALDH1A1KMT2APKMLMNA | |
| SCHEMBL18876391 | 0.84 | MAPT (0.51) | MAPTALDH1A1KMT2APKMLMNA | |
| SCHEMBL4248193 | 0.82 | ALDH1A1 (0.63) | MAPTALDH1A1KMT2ATHRBLMNA | |
| SCHEMBL23833822 | 0.79 | MAPT (0.41) | MAPTALDH1A1KMT2ATHRBKDM4E | |
| SCHEMBL18396735 | 0.78 | ALDH1A1 (0.66) | MAPTALDH1A1KMT2ATHRBPKM | |
| SCHEMBL4383340 | 0.77 | MAPT (0.52) | MAPTALDH1A1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL28980384 | 0.76 | ALDH1A1 (0.44) | MAPTALDH1A1KMT2ATHRBPKM | |
| SCHEMBL22698342 | 0.75 | ALDH1A1 (0.38) | MAPTALDH1A1KMT2AKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137553-A1 | Thiazepine Oxazolidinones as Antibacterial Agents | PHARMACIA AND UPJOHN COMPANY LLC (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1819702-A1 | THIAZEPINE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | Pharmacia & Upjohn Company LLC (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006056875-A1 | THIAZEPINE OXAZOLIDINONES AS ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137553-A1 | Thiazepine Oxazolidinones as Antibacterial Agents | OXA1L, TBCD, CLPP | MAPT 2991/4885ALDH1A1 2766/4885KMT2A 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.